See more : Panjit International Inc. (2481.TW) Income Statement Analysis – Financial Results
Complete financial analysis of Kiromic BioPharma, Inc. (KRBP) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Kiromic BioPharma, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Ricegrowers Limited (SGLLV.AX) Income Statement Analysis – Financial Results
- Sichuan Golden Summit (group) Joint-Stock Co., Ltd. (600678.SS) Income Statement Analysis – Financial Results
- Isuzu Motors Limited (7202.T) Income Statement Analysis – Financial Results
- Remala Abadi Tbk. (DATA.JK) Income Statement Analysis – Financial Results
- Shionogi & Co., Ltd. (SGIOY) Income Statement Analysis – Financial Results
Kiromic BioPharma, Inc. (KRBP)
About Kiromic BioPharma, Inc.
Kiromic BioPharma, Inc., an artificial intelligence driven allogeneic cell therapy company, engages in developing the multi-indication allogeneic T cell therapies that exploits the natural potency of the Gamma Delta T cell to target solid tumors. The company develops ALEXIS-ISO-1, an allogenic gamma delta CAR-T cell therapy product candidate targeting Isomesothelin; and ALEXIS-PRO-1, an allogeneic gamma delta chimeric T cell therapy product candidate targeting PD-L1. It has license agreements with CGA 369 Intellectual Holdings, Inc. and Longwood University, as well as a research and development collaboration agreement with Molipharma, S.R.L. The company also has strategic alliance agreement with Leon Office (H.K.) Ltd. The company was formerly known as Kiromic, Inc. and changed its name to Kiromic BioPharma, Inc. in December 2019. Kiromic BioPharma, Inc. was founded in 2006 and is headquartered in Houston, Texas.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 2.80M | 2.07M | 469.80K | 200.00K | 87.50K | 80.90K |
| Gross Profit | -2.80M | -2.07M | -469.80K | -200.00K | -87.50K | -80.90K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 9.62M | 13.92M | 11.37M | 5.05M | 1.20M | 1.42M |
| General & Administrative | 10.31M | 17.19M | 13.94M | 14.14M | 2.50M | 1.76M |
| Selling & Marketing | -2.80M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 7.52M | 17.19M | 13.94M | 14.14M | 2.50M | 1.76M |
| Other Expenses | 0.00 | 0.00 | 53.40K | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 17.14M | 31.11M | 25.31M | 19.20M | 3.71M | 3.18M |
| Cost & Expenses | 19.94M | 31.11M | 25.31M | 19.20M | 3.71M | 3.18M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | -1.85M | 166.50K | 12.20K | 3.30K | 22.50K | 633.10K |
| Depreciation & Amortization | 2.80M | 2.07M | 469.80K | 200.00K | 87.50K | 80.90K |
| EBITDA | -16.30M | -32.50M | -25.74M | -19.00M | -3.62M | -3.10M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -19.94M | -31.11M | -25.74M | -19.20M | -3.71M | -3.18M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -1.01M | -3.62M | 147.00K | -3.30K | -22.50K | -633.10K |
| Income Before Tax | -20.95M | -34.73M | -25.59M | -19.20M | -3.73M | -3.82M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 3.45M | 65.60K | 3.30K | 22.50K | -80.24K |
| Net Income | -21.29M | -38.18M | -25.65M | -19.20M | -3.75M | -3.82M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -21.41 | -70.12 | -67.40 | -79.08 | -29.00 | -32.40 |
| EPS Diluted | -21.41 | -70.12 | -67.40 | -79.08 | -29.00 | -32.40 |
| Weighted Avg Shares Out | 1.10M | 544.53K | 380.61K | 242.83K | 129.32K | 117.76K |
| Weighted Avg Shares Out (Dil) | 1.10M | 544.53K | 380.61K | 242.83K | 129.32K | 117.76K |
Kiromic BioPharma and Beverly Hills Cancer Center Enter Clinical Trial Agreement
HOUSTON--(BUSINESS WIRE)---- $KRBP #CART--Kiromic BioPharma, Inc. (OTC PINK: KRBP) (“Kiromic” or the “Company”), a clinical-stage, fully-integrated biotherapeutics company using its proprietary DIAMOND® artificial intelligence and data mining platform to develop cell therapies with a focus on immuno-oncology, announces the execution...
Kiromic BioPharma Common Stock to Begin Trading on the OTC Pink Sheets on September 14
HOUSTON--(BUSINESS WIRE)-- #CART--Kiromic BioPharma (NASDAQ: KRBP) (“Kiromic” or the “Company”), a clinical-stage, fully-integrated biotherapeutics company using its proprietary DIAMOND® artificial intelligence and data mining platform to develop cell therapies with a focus on immuno-oncology, announces that on September 12, 2023...
Kiromic BioPharma Welcomes Two New Directors to its Board
HOUSTON--(BUSINESS WIRE)-- #CART--Kiromic BioPharma, Inc. (NASDAQ: KRBP) (“Kiromic” or the “Company”), a clinical-stage, fully-integrated biotherapeutics company using its proprietary DIAMOND® artificial intelligence and data mining platform to develop cell therapies with a focus on immuno-oncology, announces the appointments of Pamela...
10 Hot Penny Stocks Under $1 To Watch This Week
Penny stocks under $1 to watch right now. The post 10 Hot Penny Stocks Under $1 To Watch This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
KRBP Shareholder Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Shareholders of Kiromic BioPharma, Inc. of Deadline in Securities Fraud Class Action Lawsuit
RADNOR, Pa., Oct. 2, 2022 /PRNewswire/ — The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Kiromic BioPharma, Inc. (“Kiromic”) (NASDAQ: KRBP). The action charges Kiromic...
Long Term Penny Stocks Investing Strategy (Complete Guide)
Use this guide for investing in penny stocks in the long term The post Long Term Penny Stocks Investing Strategy (Complete Guide) appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Kiromic BioPharma, Inc. Shareholder Reminder: Kessler Topaz Meltzer & Check, LLP Reminds KRBP Investors of Securities Fraud Class Action Lawsuit Filed On Their Behalf
RADNOR, Pa.--(BUSINESS WIRE)---- $PINS #classaction--The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Kiromic BioPharma, Inc. (“Kiromic”) (NASDAQ: KRBP). The action charges Kiromic with violations of...
ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Kiromic BioPharma, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – KRBP
NEW YORK, Sept. 8, 2022 /PRNewswire/ — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Kiromic BioPharma, Inc. (NASDAQ: KRBP): (i) pursuant and/or traceable to the offering documents issued in connection with...
INVESTOR NOTIFICATION: Kessler Topaz Meltzer & Check, LLP Announces Lead Plaintiff Deadline on October 4, 2022 in Securities Fraud Class Action Lawsuit Filed against Kiromic BioPharma, Inc.
RADNOR, Pa., Aug. 29, 2022 /PRNewswire/ — The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Kiromic BioPharma, Inc. (“Kiromic”) (NASDAQ: KRBP). The action charges Kiromic...
Why Kiromic BioPharma Shares Are Trading Higher Today?
Kiromic BioPharma Inc (NASDAQ: KRBP) has completed the construction of its expanded current good manufacturing practice manufacturing facility in Houston. The expanded facility located at Kiromic's headquarters is one of the conditions required for the Company to begin.
Source: https://incomestatements.info
Category: Stock Reports